Francesco Dentali1, Walter Ageno2, Elisa Rumi3, Ilaria Casetti3, Daniela Poli4, Umberto Scoditti5, Margherita Maffioli6, Matteo Nicola Dario di Minno7, Domenica Caramazza6, Daniela Pietra3, Valerio De Stefano8, Francesco Passamonti6. 1. Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy. Electronic address: fdentali@libero.it. 2. Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy. 3. Department of Hematology Oncology, University of Pavia, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. 4. Thrombosis Centre Department of Heart and Vessels, AOU-Careggi, Florence, Italy. 5. Departement of Neurology, University of Parma, Parma, Italy. 6. Division of Hematology, Department of Internal Medicine, Ospedale di Circolo & Fondazione Macchi, Varese, Italy. 7. Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy. 8. Institute of Hematology, Catholic University, Largo Gemelli, Rome, Italy.
Abstract
INTRODUCTION: Myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Patients with MPNs are prone to develop arterial and venous thrombosis either at diagnosis or during follow-up; in particular splancnic vein is strongly associated with MPN. Conversely, presence of MPN is uncommon in patients with deep vein thrombosis of the lower extremities and with pulmonary embolism. Only few studies with conflicting results have evaluated the prevalence of an underlying MPN in patients with cerebral venous thrombosis (CVT), and limited evidence exists on the incidence of CVT in patients with established MPN. METHODS: We assessed the frequency of MPNs in a series of 706 patients with cerebral vein thrombosis (CVT) and the frequency of CVT in a cohort of 2,143 MPNs patients. RESULTS: Twenty-seven CVT patients (3.8%) were diagnosed with MPN: 9 before CVT (1.3%), 4 concomitantly (0.6%), and 14 after CVT (2.0%). Nine CVT cases (0.4%) were diagnosed in the MPN cohort, with a slightly higher frequency in PV (five of 735, 0.7%) than in ET (three of 964, 0.3%) and in PMF (one of 444, 0.2%). CONCLUSION: Considering the analyses of these databases jointly, the results obtained suggest a weak association between CVT and MPNs and ultimately suggest that a thorough investigation looking for an underlying MPN may not be warranted in all the patients with CVT without overt myeloproliferative features.
INTRODUCTION:Myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Patients with MPNs are prone to develop arterial and venous thrombosis either at diagnosis or during follow-up; in particular splancnic vein is strongly associated with MPN. Conversely, presence of MPN is uncommon in patients with deep vein thrombosis of the lower extremities and with pulmonary embolism. Only few studies with conflicting results have evaluated the prevalence of an underlying MPN in patients with cerebral venous thrombosis (CVT), and limited evidence exists on the incidence of CVT in patients with established MPN. METHODS: We assessed the frequency of MPNs in a series of 706 patients with cerebral vein thrombosis (CVT) and the frequency of CVT in a cohort of 2,143 MPNs patients. RESULTS: Twenty-seven CVT patients (3.8%) were diagnosed with MPN: 9 before CVT (1.3%), 4 concomitantly (0.6%), and 14 after CVT (2.0%). Nine CVT cases (0.4%) were diagnosed in the MPN cohort, with a slightly higher frequency in PV (five of 735, 0.7%) than in ET (three of 964, 0.3%) and in PMF (one of 444, 0.2%). CONCLUSION: Considering the analyses of these databases jointly, the results obtained suggest a weak association between CVT and MPNs and ultimately suggest that a thorough investigation looking for an underlying MPN may not be warranted in all the patients with CVT without overt myeloproliferative features.
Authors: Patrick Lilienthal; Manuel Tetschke; Enrico Schalk; Thomas Fischer; Sebastian Sager Journal: Front Physiol Date: 2020-04-17 Impact factor: 4.566
Authors: Eva N Hamulyák; Joost G Daams; Frank W G Leebeek; Bart J Biemond; Peter A W Te Boekhorst; Saskia Middeldorp; Mandy N Lauw Journal: Blood Adv Date: 2021-01-12
Authors: Barbara Mora; Paola Guglielmelli; Andrew Kuykendall; Elisa Rumi; Margherita Maffioli; Francesca Palandri; Valerio De Stefano; Marianna Caramella; Silvia Salmoiraghi; Jean-Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Marco Ruggeri; Richard T Silver; Francesco Albano; Giulia Benevolo; David M Ross; Matteo G Della Porta; Timothy Devos; Giada Rotunno; Rami S Komrokji; Ilaria C Casetti; Michele Merli; Marco Brociner; Domenica Caramazza; Giuseppe Auteri; Tiziano Barbui; Daniele Cattaneo; Lorenza Bertù; Luca Arcaini; Alessandro M Vannucchi; Francesco Passamonti Journal: Leukemia Date: 2022-08-30 Impact factor: 12.883